Trans-Tenon's retrobulbar triamcinolone acetonide infusion for refractory diabetic macular edema after vitrectomy
To evaluate the efficacy and safety of trans-Tenon's retrobulbar triamcinolone acetonide (TA) infusion for the treatment of refractory diabetic macular edema (DME) after vitrectomy. After topical anesthesia, 20 eyes from 20 patients with persistent DME after pars plana vitrectomy were treated w...
Gespeichert in:
| Veröffentlicht in: | Graefe's archive for clinical and experimental ophthalmology 2005-12, Vol.243 (12), p.1247-1252 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1252 |
|---|---|
| container_issue | 12 |
| container_start_page | 1247 |
| container_title | Graefe's archive for clinical and experimental ophthalmology |
| container_volume | 243 |
| creator | Koga, Tomoyo Mawatari, Yuki Inumaru, Junko Fukushima, Mikiko Tanihara, Hidenobu |
| description | To evaluate the efficacy and safety of trans-Tenon's retrobulbar triamcinolone acetonide (TA) infusion for the treatment of refractory diabetic macular edema (DME) after vitrectomy.
After topical anesthesia, 20 eyes from 20 patients with persistent DME after pars plana vitrectomy were treated with trans-Tenon's retrobulbar infusion of 40 mg TA through an inferotemporal approach. The mean duration (+/-SD) between vitrectomy and trans-Tenon's retrobulbar TA infusion was 11.4+/-7.9 months. The mean follow-up period (+/-SD) after trans-Tenon's retrobulbar TA infusion was 13.3+/-2.8 months.
At 1 week after trans-Tenon's retrobulbar TA infusion, the mean central retinal thickness (+/-SD) measured by optical coherence tomography was 381+/-99 mum, which was a statistically significant decrease in comparison with the preoperative thickness (555+/-112 mum) (P |
| doi_str_mv | 10.1007/s00417-005-0045-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68836341</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68836341</sourcerecordid><originalsourceid>FETCH-LOGICAL-c392t-78e3873d602ca8cf5cdf744bd112369e6fae44e2d4d37c0b8f42515ef125e6043</originalsourceid><addsrcrecordid>eNpdkcFrFTEQxoNY7LP6B3iR4KGetmaS7CbvKMWqUPDyhN5CNplAym7SJlnh_femvAeCh5m5_L6PmfkI-QDsBhhTXypjEtTA2NhL9vaK7ECKcVCMP7wmO6Y4DFrwh0vyttZH1iExwhtyCRPjIPdqR54PxaY6HDDl9LnSgq3keVtmW2gr0a4uprzkhNQ6bDlFjzSmsNWYEw25dEEo1rVcjtRHO2OLjq7WbUs3QI-rpTY0LPRPbAU7tx7fkYtgl4rvz_OK_L77drj9Mdz_-v7z9uv94MSet0FpFFoJ3zd1VrswOh-UlLMH4GLa4xQsSoncSy-UY7MOko8wYgA-4tQPvSLXJ9-nkp83rM2ssTpcFpswb9VMWotJSOjgp__Ax7yV1HczXDANoPa6Q3CCXMm19qvNU4mrLUcDzLyEYU5hmB6GeQnDsK75eDbe5hX9P8X5--IvbVyG6w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>230811798</pqid></control><display><type>article</type><title>Trans-Tenon's retrobulbar triamcinolone acetonide infusion for refractory diabetic macular edema after vitrectomy</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Koga, Tomoyo ; Mawatari, Yuki ; Inumaru, Junko ; Fukushima, Mikiko ; Tanihara, Hidenobu</creator><creatorcontrib>Koga, Tomoyo ; Mawatari, Yuki ; Inumaru, Junko ; Fukushima, Mikiko ; Tanihara, Hidenobu</creatorcontrib><description>To evaluate the efficacy and safety of trans-Tenon's retrobulbar triamcinolone acetonide (TA) infusion for the treatment of refractory diabetic macular edema (DME) after vitrectomy.
After topical anesthesia, 20 eyes from 20 patients with persistent DME after pars plana vitrectomy were treated with trans-Tenon's retrobulbar infusion of 40 mg TA through an inferotemporal approach. The mean duration (+/-SD) between vitrectomy and trans-Tenon's retrobulbar TA infusion was 11.4+/-7.9 months. The mean follow-up period (+/-SD) after trans-Tenon's retrobulbar TA infusion was 13.3+/-2.8 months.
At 1 week after trans-Tenon's retrobulbar TA infusion, the mean central retinal thickness (+/-SD) measured by optical coherence tomography was 381+/-99 mum, which was a statistically significant decrease in comparison with the preoperative thickness (555+/-112 mum) (P<0.001). Additional trans-Tenon's retrobulbar TA infusions were performed in ten eyes (50%), due to the recurrence of DME at 6.6+/-3.0 months after the first TA infusion. At the final examination, macular edema resolved in 13 (65%), improved in four (20%), and remained unchanged in three (15%) of the 20 eyes. At 1 month after trans-Tenon's retrobulbar TA infusion, the mean laser flare value (+/-SD) was 9.6+/-3.0 photon/ms, which was a statistically significant decrease in comparison with the preoperative value (15.5+/-5.9 photon/ms) (P<0.01). Furthermore, in ten eyes (50%) with recurrent DME, re-elevated laser flare values were observed prior to the recurrence of DME. The final best-corrected Snellen visual acuity improved by two or more lines in nine eyes (45%), and remained unchanged in 11 eyes (55.0%). IOP elevation equal to or higher than 21 mmHg was observed in three (15%) of the 20 eyes with TA infusion, and was controlled by topical medications. No other injection-related complications were observed.
Trans-Tenon's retrobulbar TA infusion is an effective and safe method for the treatment of refractory DME, which is present even after vitrectomy.</description><identifier>ISSN: 0721-832X</identifier><identifier>EISSN: 1435-702X</identifier><identifier>DOI: 10.1007/s00417-005-0045-0</identifier><identifier>PMID: 16021497</identifier><language>eng</language><publisher>Germany: Springer Nature B.V</publisher><subject>Adult ; Aged ; Diabetic Retinopathy - drug therapy ; Diabetic Retinopathy - pathology ; Female ; Follow-Up Studies ; Glucocorticoids - administration & dosage ; Glucocorticoids - therapeutic use ; Humans ; Injections ; Macular Edema - drug therapy ; Macular Edema - etiology ; Macular Edema - pathology ; Male ; Middle Aged ; Orbit ; Retina - pathology ; Retrospective Studies ; Tomography, Optical Coherence ; Triamcinolone Acetonide - administration & dosage ; Triamcinolone Acetonide - therapeutic use ; Vitrectomy - adverse effects ; Vitreous Hemorrhage - surgery</subject><ispartof>Graefe's archive for clinical and experimental ophthalmology, 2005-12, Vol.243 (12), p.1247-1252</ispartof><rights>Springer-Verlag 2005</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c392t-78e3873d602ca8cf5cdf744bd112369e6fae44e2d4d37c0b8f42515ef125e6043</citedby><cites>FETCH-LOGICAL-c392t-78e3873d602ca8cf5cdf744bd112369e6fae44e2d4d37c0b8f42515ef125e6043</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16021497$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Koga, Tomoyo</creatorcontrib><creatorcontrib>Mawatari, Yuki</creatorcontrib><creatorcontrib>Inumaru, Junko</creatorcontrib><creatorcontrib>Fukushima, Mikiko</creatorcontrib><creatorcontrib>Tanihara, Hidenobu</creatorcontrib><title>Trans-Tenon's retrobulbar triamcinolone acetonide infusion for refractory diabetic macular edema after vitrectomy</title><title>Graefe's archive for clinical and experimental ophthalmology</title><addtitle>Graefes Arch Clin Exp Ophthalmol</addtitle><description>To evaluate the efficacy and safety of trans-Tenon's retrobulbar triamcinolone acetonide (TA) infusion for the treatment of refractory diabetic macular edema (DME) after vitrectomy.
After topical anesthesia, 20 eyes from 20 patients with persistent DME after pars plana vitrectomy were treated with trans-Tenon's retrobulbar infusion of 40 mg TA through an inferotemporal approach. The mean duration (+/-SD) between vitrectomy and trans-Tenon's retrobulbar TA infusion was 11.4+/-7.9 months. The mean follow-up period (+/-SD) after trans-Tenon's retrobulbar TA infusion was 13.3+/-2.8 months.
At 1 week after trans-Tenon's retrobulbar TA infusion, the mean central retinal thickness (+/-SD) measured by optical coherence tomography was 381+/-99 mum, which was a statistically significant decrease in comparison with the preoperative thickness (555+/-112 mum) (P<0.001). Additional trans-Tenon's retrobulbar TA infusions were performed in ten eyes (50%), due to the recurrence of DME at 6.6+/-3.0 months after the first TA infusion. At the final examination, macular edema resolved in 13 (65%), improved in four (20%), and remained unchanged in three (15%) of the 20 eyes. At 1 month after trans-Tenon's retrobulbar TA infusion, the mean laser flare value (+/-SD) was 9.6+/-3.0 photon/ms, which was a statistically significant decrease in comparison with the preoperative value (15.5+/-5.9 photon/ms) (P<0.01). Furthermore, in ten eyes (50%) with recurrent DME, re-elevated laser flare values were observed prior to the recurrence of DME. The final best-corrected Snellen visual acuity improved by two or more lines in nine eyes (45%), and remained unchanged in 11 eyes (55.0%). IOP elevation equal to or higher than 21 mmHg was observed in three (15%) of the 20 eyes with TA infusion, and was controlled by topical medications. No other injection-related complications were observed.
Trans-Tenon's retrobulbar TA infusion is an effective and safe method for the treatment of refractory DME, which is present even after vitrectomy.</description><subject>Adult</subject><subject>Aged</subject><subject>Diabetic Retinopathy - drug therapy</subject><subject>Diabetic Retinopathy - pathology</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Glucocorticoids - administration & dosage</subject><subject>Glucocorticoids - therapeutic use</subject><subject>Humans</subject><subject>Injections</subject><subject>Macular Edema - drug therapy</subject><subject>Macular Edema - etiology</subject><subject>Macular Edema - pathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Orbit</subject><subject>Retina - pathology</subject><subject>Retrospective Studies</subject><subject>Tomography, Optical Coherence</subject><subject>Triamcinolone Acetonide - administration & dosage</subject><subject>Triamcinolone Acetonide - therapeutic use</subject><subject>Vitrectomy - adverse effects</subject><subject>Vitreous Hemorrhage - surgery</subject><issn>0721-832X</issn><issn>1435-702X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpdkcFrFTEQxoNY7LP6B3iR4KGetmaS7CbvKMWqUPDyhN5CNplAym7SJlnh_femvAeCh5m5_L6PmfkI-QDsBhhTXypjEtTA2NhL9vaK7ECKcVCMP7wmO6Y4DFrwh0vyttZH1iExwhtyCRPjIPdqR54PxaY6HDDl9LnSgq3keVtmW2gr0a4uprzkhNQ6bDlFjzSmsNWYEw25dEEo1rVcjtRHO2OLjq7WbUs3QI-rpTY0LPRPbAU7tx7fkYtgl4rvz_OK_L77drj9Mdz_-v7z9uv94MSet0FpFFoJ3zd1VrswOh-UlLMH4GLa4xQsSoncSy-UY7MOko8wYgA-4tQPvSLXJ9-nkp83rM2ssTpcFpswb9VMWotJSOjgp__Ax7yV1HczXDANoPa6Q3CCXMm19qvNU4mrLUcDzLyEYU5hmB6GeQnDsK75eDbe5hX9P8X5--IvbVyG6w</recordid><startdate>20051201</startdate><enddate>20051201</enddate><creator>Koga, Tomoyo</creator><creator>Mawatari, Yuki</creator><creator>Inumaru, Junko</creator><creator>Fukushima, Mikiko</creator><creator>Tanihara, Hidenobu</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20051201</creationdate><title>Trans-Tenon's retrobulbar triamcinolone acetonide infusion for refractory diabetic macular edema after vitrectomy</title><author>Koga, Tomoyo ; Mawatari, Yuki ; Inumaru, Junko ; Fukushima, Mikiko ; Tanihara, Hidenobu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c392t-78e3873d602ca8cf5cdf744bd112369e6fae44e2d4d37c0b8f42515ef125e6043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Diabetic Retinopathy - drug therapy</topic><topic>Diabetic Retinopathy - pathology</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Glucocorticoids - administration & dosage</topic><topic>Glucocorticoids - therapeutic use</topic><topic>Humans</topic><topic>Injections</topic><topic>Macular Edema - drug therapy</topic><topic>Macular Edema - etiology</topic><topic>Macular Edema - pathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Orbit</topic><topic>Retina - pathology</topic><topic>Retrospective Studies</topic><topic>Tomography, Optical Coherence</topic><topic>Triamcinolone Acetonide - administration & dosage</topic><topic>Triamcinolone Acetonide - therapeutic use</topic><topic>Vitrectomy - adverse effects</topic><topic>Vitreous Hemorrhage - surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Koga, Tomoyo</creatorcontrib><creatorcontrib>Mawatari, Yuki</creatorcontrib><creatorcontrib>Inumaru, Junko</creatorcontrib><creatorcontrib>Fukushima, Mikiko</creatorcontrib><creatorcontrib>Tanihara, Hidenobu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Graefe's archive for clinical and experimental ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Koga, Tomoyo</au><au>Mawatari, Yuki</au><au>Inumaru, Junko</au><au>Fukushima, Mikiko</au><au>Tanihara, Hidenobu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Trans-Tenon's retrobulbar triamcinolone acetonide infusion for refractory diabetic macular edema after vitrectomy</atitle><jtitle>Graefe's archive for clinical and experimental ophthalmology</jtitle><addtitle>Graefes Arch Clin Exp Ophthalmol</addtitle><date>2005-12-01</date><risdate>2005</risdate><volume>243</volume><issue>12</issue><spage>1247</spage><epage>1252</epage><pages>1247-1252</pages><issn>0721-832X</issn><eissn>1435-702X</eissn><abstract>To evaluate the efficacy and safety of trans-Tenon's retrobulbar triamcinolone acetonide (TA) infusion for the treatment of refractory diabetic macular edema (DME) after vitrectomy.
After topical anesthesia, 20 eyes from 20 patients with persistent DME after pars plana vitrectomy were treated with trans-Tenon's retrobulbar infusion of 40 mg TA through an inferotemporal approach. The mean duration (+/-SD) between vitrectomy and trans-Tenon's retrobulbar TA infusion was 11.4+/-7.9 months. The mean follow-up period (+/-SD) after trans-Tenon's retrobulbar TA infusion was 13.3+/-2.8 months.
At 1 week after trans-Tenon's retrobulbar TA infusion, the mean central retinal thickness (+/-SD) measured by optical coherence tomography was 381+/-99 mum, which was a statistically significant decrease in comparison with the preoperative thickness (555+/-112 mum) (P<0.001). Additional trans-Tenon's retrobulbar TA infusions were performed in ten eyes (50%), due to the recurrence of DME at 6.6+/-3.0 months after the first TA infusion. At the final examination, macular edema resolved in 13 (65%), improved in four (20%), and remained unchanged in three (15%) of the 20 eyes. At 1 month after trans-Tenon's retrobulbar TA infusion, the mean laser flare value (+/-SD) was 9.6+/-3.0 photon/ms, which was a statistically significant decrease in comparison with the preoperative value (15.5+/-5.9 photon/ms) (P<0.01). Furthermore, in ten eyes (50%) with recurrent DME, re-elevated laser flare values were observed prior to the recurrence of DME. The final best-corrected Snellen visual acuity improved by two or more lines in nine eyes (45%), and remained unchanged in 11 eyes (55.0%). IOP elevation equal to or higher than 21 mmHg was observed in three (15%) of the 20 eyes with TA infusion, and was controlled by topical medications. No other injection-related complications were observed.
Trans-Tenon's retrobulbar TA infusion is an effective and safe method for the treatment of refractory DME, which is present even after vitrectomy.</abstract><cop>Germany</cop><pub>Springer Nature B.V</pub><pmid>16021497</pmid><doi>10.1007/s00417-005-0045-0</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0721-832X |
| ispartof | Graefe's archive for clinical and experimental ophthalmology, 2005-12, Vol.243 (12), p.1247-1252 |
| issn | 0721-832X 1435-702X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68836341 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Aged Diabetic Retinopathy - drug therapy Diabetic Retinopathy - pathology Female Follow-Up Studies Glucocorticoids - administration & dosage Glucocorticoids - therapeutic use Humans Injections Macular Edema - drug therapy Macular Edema - etiology Macular Edema - pathology Male Middle Aged Orbit Retina - pathology Retrospective Studies Tomography, Optical Coherence Triamcinolone Acetonide - administration & dosage Triamcinolone Acetonide - therapeutic use Vitrectomy - adverse effects Vitreous Hemorrhage - surgery |
| title | Trans-Tenon's retrobulbar triamcinolone acetonide infusion for refractory diabetic macular edema after vitrectomy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T18%3A26%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Trans-Tenon's%20retrobulbar%20triamcinolone%20acetonide%20infusion%20for%20refractory%20diabetic%20macular%20edema%20after%20vitrectomy&rft.jtitle=Graefe's%20archive%20for%20clinical%20and%20experimental%20ophthalmology&rft.au=Koga,%20Tomoyo&rft.date=2005-12-01&rft.volume=243&rft.issue=12&rft.spage=1247&rft.epage=1252&rft.pages=1247-1252&rft.issn=0721-832X&rft.eissn=1435-702X&rft_id=info:doi/10.1007/s00417-005-0045-0&rft_dat=%3Cproquest_cross%3E68836341%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=230811798&rft_id=info:pmid/16021497&rfr_iscdi=true |